Premium
S‐phase fraction of human prostate adenocarcinoma studied with in vivo bromodeoxyuridine labeling
Author(s) -
Nemoto Ryosuke,
Hattori Kazunori,
Uchida Katsunori,
Shimazui Toru,
Nishijima Yukiko,
Koiso Kenkichi,
Harada Masaoki
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19900801)66:3<509::aid-cncr2820660318>3.0.co;2-#
Subject(s) - bromodeoxyuridine , immunoperoxidase , medicine , prostate , pathology , prostate cancer , in vivo , adenocarcinoma , malignancy , biopsy , monoclonal antibody , cancer , antibody , immunohistochemistry , biology , immunology , microbiology and biotechnology
Forty‐six patients with adenocarcinoma of the prostate were given an intravenous infusion of the thymidine analogue, bromodeoxyuridine (BrdU), 200 mg/m 2 , at the time of needle biopsy or transurethral resection to label tumor cells in the DNA synthesis phase. The tumor specimens were stained by an indirect immunoperoxidase method with anti‐BrdU monoclonal antibody. The BrdU labeling index, S‐phase fraction, was determined by counting the number of BrdU‐labeled cells in the tissue sections. S‐phase fraction correlates with the results of histologic tumor grade, Gleason score, and growth patterns. The higher S‐phase fraction may indicate biologic malignancy. Moreover, the degree of heterogeneity concerning S‐phase fraction distribution within prostate cancer tissue could be evaluated and the findings compared with the morphologic appearance. The authors results suggest that the measurement of BrdU labeling index in prostate cancer may prove to be a new objective and quantitative assay for biologic potential of individual tumors.